1型糖尿病老年成人骨密度降低的危险因素:横断面研究
本研究基于美国与加拿大27个中心的糖尿病干预与并发症流行病学研究(EDIC)队列,纳入1058例完成DXA扫描的1型糖尿病老年患者,评估糖尿病相关因素与全髋骨密度的关联。结果显示较高的平均HbA1c、较高的皮肤内在荧光和肾脏疾病与较低的全髋骨密度独立相关,而视网膜病变和神经病变无此关联。
要点
- 平均HbA1c每升高1%,全髋骨密度降低10.7 mg/cm2(95%CI -19.6至-1.7)。
- 皮肤内在荧光每升高5单位,全髋骨密度降低20.5 mg/cm2(95%CI -29.9至-11.0)。
- 合并肾脏疾病者全髋骨密度降低51.7 mg/cm2(95%CI -80.6至-22.7)。
核心结论
- 较差的血糖控制、AGE积累和肾脏疾病是1型糖尿病老年成人髋部骨密度降低的独立危险因素。
- 维持血糖控制和预防肾脏疾病可能减少该人群的骨丢失并最终减少骨折。
- 对具有这些危险因素的人群,骨质疏松筛查可能尤其重要。
- 进一步研究识别AGE阻断剂可能有益于骨骼健康。
研究设计与样本
- 横断面研究,嵌入长期观察性研究EDIC,该队列为原DCCT入组、在美国和加拿大27个中心随访超过30年的1型糖尿病参与者。
- 所有活跃的EDIC参与者均符合条件,妊娠、体重超过双能X线吸收仪(DXA)扫描上限、植入神经刺激器或不自愿参与者除外。
- 主要研究结局为全髋骨密度,于2017-19年一次年度EDIC访视时用DXA测量髋、脊柱、桡骨骨密度及骨小梁评分(TBS)。
- EDIC期间每年测量时间加权平均HbA1c、肾脏疾病和外周神经病变,每4年测量视网膜病变;2009-10年一次性评估皮肤内在荧光(AGEs指标)和心脏自主神经病变。
- 1094例参与者接受筛查,1058例完成至少一项DXA扫描并纳入分析。
主要发现
- 纳入分析的1058例中,女性占47.8%,男性占52.2%,白人占96.6%,其他种族或族裔占3.4%,平均年龄59.2岁(SD 6.7)。
- 较高的平均HbA1c、较高的皮肤内在荧光和肾脏疾病(而非视网膜病变或神经病变)与较低的全髋骨密度独立相关。
- 全髋骨密度:平均HbA1c每升高1%降低10.7 mg/cm2(95%CI -19.6至-1.7);皮肤内在荧光每升高5单位降低20.5 mg/cm2(95%CI -29.9至-11.0);合并肾脏疾病者降低51.7 mg/cm2(95%CI -80.6至-22.7)。
- 股骨颈和桡骨超远端骨密度呈相似关联,但腰椎骨密度和TBS无此关联。
关键数值与推荐
- 平均HbA1c每升高1%:全髋骨密度变化-10.7 mg/cm2(95%CI -19.6至-1.7)。
- 皮肤内在荧光每升高5单位:全髋骨密度变化-20.5 mg/cm2(95%CI -29.9至-11.0)。
- 合并肾脏疾病:全髋骨密度变化-51.7 mg/cm2(95%CI -80.6至-22.7)。
临床怎么用
- 作者认为,维持血糖控制和预防肾脏疾病可能减少该人群的骨丢失并最终减少骨折。
- 作者认为,对具有上述危险因素的人群,骨质疏松筛查可能尤其重要。
- 作者认为,进一步研究识别AGE阻断剂可能有益于骨骼健康。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 1 diabetes is associated with lower bone mineral density (BMD) and increased fracture risk, but little is known regarding the effects of diabetes-related factors on BMD. We assessed whether these factors are associated with lower hip BMD among older adults with type 1 diabetes. METHODS: This cross-sectional study was embedded in a long-term observational study, the Epidemiology of Diabetes Interventions and Complications study (EDIC), a cohort of participants with type 1 diabetes, who were originally enrolled in the Diabetes Control and Complications Trial (DCCT), and were followed-up for more than 30 years at 27 sites in the USA and Canada. All active EDIC participants were eligible except if they were pregnant, weighed above the dual-energy x-ray absorptiometry (DXA) scanner limit, had an implanted neurostimulator, or were not willing to participate. The primary study outcome was total hip BMD. Hip, spine, and radius BMD and trabecular bone score (TBS) were measured with DXA at an annual EDIC visit (2017-19). Time-weighted mean HbA1c, kidney disease, and peripheral neuropathy were measured annually during EDIC, and retinopathy was measured every 4 years. Skin intrinsic fluorescence, a measure of advanced glycation end products (AGEs), and cardiac autonomic neuropathy were assessed once (2009-10) during EDIC. FINDINGS: 1147 of the 1441 participants who were enrolled in the DCCT trial remained active EDIC participants at the start of this cross-sectional study. Between Sept 20, 2017, and Sept 19, 2019, 1094 of 1147 participants were screened for the EDIC Skeletal Health study. 1058 participants completed at least one of a set of DXA scans and were included in the analysis. 47·8% were women and 52·2% were men, 96·6% were White and 3·4% were of other race or ethnicity. The mean age of participants was 59·2 years (SD 6·7). Higher mean HbA1c, higher skin intrinsic fluorescence, and kidney disease (but not retinopathy or neuropathy) were independently associated with a lower total hip BMD. Total hip BMD differed by -10·7 mg/cm2 (95% CI -19·6 to -1·7) for each 1% increase in mean HbA1c, -20·5 mg/cm2 (-29·9 to -11·0) for each 5 unit higher skin intrinsic fluorescence, and -51·7 mg/cm2 (-80·6 to -22·7) in the presence of kidney disease. Similar associations were found for femoral neck and ultra-distal radius BMD, but not for lumbar spine BMD or TBS. INTERPRETATION: Poorer glycaemic control, AGE accumulation, and kidney disease are independent risk factors for lower hip BMD in older adults with type 1 diabetes. Maintenance of glycaemic control and prevention of kidney disease might reduce bone loss and ultimately fractures in this population. Osteoporosis screening might be particularly important in people with these risk factors. Further research to identify AGE blockers could benefit skeletal health. FUNDING: National Institute of Diabetes and Digestive and Kidney Disease.
引用
- Schwartz AV, Backlund JC, de Boer IH, et al. Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes Endocrinol. 2022. PMID: 35576955. doi:10.1016/S2213-8587(22)00103-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。